Gastric cancer • Neogenin-1 • Epithelial mesenchymal transition • Zinc finger E-box-binding homeobox 1 • Rac1/PI3K/AKT Abstract Background/Aims: Neogenin-1 (Neo1) has been reported to be involved in diverse physiology and pathology functions, including cell proliferation, differentiation and migration. The present study aimed to explore the functional role of neogenin-1 (Neo1) in gastric cancer (GC), together with underlying mechanisms. Methods: Neo1 expression was analyzed by qRT-PCR and Western blot analysis in both human GC cell lines and normal gastric epithelial cell line. Neo1 was respectively overexpressed or silenced by transfection with pcDNA3.1 or siRNA, and then the cells were incubated with or without different concentrations of cisplatin, transforming growth factor (TGF)-β1, and/or inhibitors of Rac-1 and PI3K. Thereafter, cell viability, invasion, and adhesion were measured by CCK-8, wound healing and adhesion assays, respectively. The expression levels of key factors involved in epithelial mesenchymal transition (EMT) and the PI3K/AKT pathway were analyzed by Western blot analysis.
Introduction

Cell viability and cell survival
The effects of Neo1 abnormal expression on cell viability and cell survival rate were determined by Dojindo Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Kumamoto, Japan). Briefly, SGC-7901 cells were seeded in a 96-well plate (5 × 10 3 cells/well), and then the cells were transfected with pc-Neo1, si-Neo1, or their corresponding controls. For the cell survival rate, the cells were incubated with or without different concentrations of cisplatin (0, 50, 100, 150, and 200 μM) after transfection. Subsequently, the CCK-8 solution was added to the culture medium, and then cells were incubated for 1 h at 37°C in humidified 95% air and 5% CO 2 . Absorbance at 450 nm was measured using a Microplate Reader (DTX 800, Beckman, CA, USA).
Wound healing assay
The effects of Neo1 abnormal expression on cell migration were evaluated using in vitro wound-healing model according to the manufacturer's instructions. In brief, SGC-7901 cells were plated in 6-well plates (1 × 10 4 cells/well) and incubated overnight. After transfection with pc-Neo1, si-Neo1, or their corresponding controls, wounds were created by scratching cell sheets with a sterile 200 μl pipette tip. Debris was removed from the wound and the edges were smoothened out with phosphate buffer solution (PBS). Photographs were acquired at 24 h by an inverted microscope (IX83, Olympus, Tokyo, Japan). The wound closure was quantitatively analyzed by Image J software (National Institutes of Health, Bethesda, MD, USA) by circling and assessing the unhealed area in the wound images. Each test was repeated in triplicate.
Adhesion assay
The effects of Neo1 abnormal expression on cell adhesion ability was analyzed by an adhesion assay according to the manufacturer's instructions. Briefly, after transfection with pc-Neo1, si-Neo1, or their corresponding controls, the SGC-7901 cells were trypsinized, suspended in 200 μl of serum-free medium and added to Matrigel-coated inserts (8-μm pore size; BD Bioscience, Franklin Lakes, NJ, USA). These cells were maintained in RPMI 1640 medium supplemented with 2% FBS. After twenty-four hours, the cells were removed from the upper surface of the membrane by a cotton-tipped swab. Thereafter, the membranes were fixed with 4% paraformaldehyde for 10 min and mounted over slides with 5 μl of Fluoromount reagent with 4, 6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich).
Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR)
Total RNA was isolated using TRIzol (Invitrogen) according to the manufacturer's instructions. RNA was reversely transcribed to complementary DNA (cDNA) using PrimeScriptTM RT Master Mix (Takara, Otsu, Japan). PCR specific primers were designed by GenePharma. The primers were listed as following: Neo1 Forward: 5'-AAATA GTCAA CAAGC ATGGT AAAAA-3' and Reverse: 5'-AAGAC ATGTC CACAG CCACA-3'; zinc finger E-box-binding homeobox 1 (ZEB1) Forward: 5'-GATGA CCTGC CAACA GACCA-3' and Reverse: 5'-CCCCA GGATT TCTTG CCCTT-3'; GAPDH Forward: 5'-GCACC GTCAA GGCTG AGAAC-3' and Reverse: 5'-TGGTG AAGAC GCCAG TGGA-3'. qRT-PCR was performed on the Bio-Rad CFX 96 Real-time PCR system (Bio-Rad, Hercules, CA) using SYBR ® Premix Ex TaqTM II (TaKaRa, Shiga, Japan) according to the manufacturer's instructions. The mRNA level was normalized to GAPDH using the comparative 2 −(∆∆Cq) method. PCR conditions were performed as the following parameters: 1 predenaturation cycle of 5 min at 94°C, 35 cycles of denaturation at 94°C for 15 s, 59°C for 45 s, and 72°C for 2 min, and a final extension at 72°C for 5 min.
Western blot
After transfection and/or treatment, the cell suspension was collected and centrifuged. Total protein was extracted from the cells using RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China). The protein concentration was quantified using a BCA™ Protein Assay Kit (Thermo Scientific, Pierce Protein Research Products, Rockford, IL, USA). Equal amount of protein (20 μg per lane) was subjected to 10-12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) gels. The protein was then transferred onto Hybond ECL 0. 45 
Statistical analysis
All experiments were repeated at least three times. Data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using the Statistics Package for Social Science 19.0 (SPSS Inc., Chicago, IL, USA). The P-values were calculated using a one-way analysis of variance (ANOVA). A P value of < 0.05 was considered statistically significant.
Results
Expression of Neo1 in GC cell lines
To investigate the functional role of Neo1 in GC, we first analyzed the expression of Neo1 in GC cell lines. The expression of Neo1 was analyzed by both qRT-PCR and Western blot. As shown in Fig. 1A-1B , both the mRNA and protein levels of Neo1 were significantly increased in GC cell lines MKN-28 (P < 0.05 for both mRNA and protein), BGC-823 (P < 0.05 for both mRNA and protein), MGC-803 (P < 0.05 for both mRNA and protein), SGC-7901 (P < 0.01 for mRNA and P < 0.001 for protein) and MKN-45 (P < 0.05 for mRNA and P < 0.01 for protein) compared to the normal gastric epithelial cell line GES-1. In addition, we found that the levels of Neo1 were the highest in SGC-7901 cells. Therefore, we chose SGC-7901 cells for further experiment. Then the cell viability, migration and invasion of SGC-7901 cells were assessed. From Fig. 1C -E, we observed that SGC-7901 cells revealed significantly high cell viability (P < 0.01 at 2 and 3 days; P < 0.001 at 4 days), migration (P < 0.01 at 2 days; P < 0.001 at 3 and 4 days), and adhesion ability (P < 0.01) compared to the normal GES-1 cells.
Effects of Neo1 abnormal expression on GC cell sensitivity to cisplatin
We then analyzed the effects of abnormal expression of Neo1 on GC cell sensitivity to cisplatin. Neo1 were overexpressed or suppressed by transfection with pc-Neo1 or si-Neo1, respectively. The transfection efficiencies were confirmed by Western blot. As indicated in Fig. 2A , the results showed that the protein levels of Neo1 were significantly increased by transfection with pc-Neo1 but dramatically decreased by transfection with si-Neo1 compared to their corresponding controls (both P < 0.001). The results implied high transfection efficiencies. The survival rate of SGC-7901 cells exposed to different concentrations of cisplatin (0, 50, 100, 150, or 200 μM) was analyzed by CCK-8 assay after transfection. As expected, the percentages of cell survival rate were significantly reduced by cisplatin in a concentration-dependent manner (Fig. 2B ). In addition, we observed that the percentages of cell survival rate were statistically upregulated by overexpression of Neo1 compared to the pc-DNA3.1 group (P < 0.05 for 100, 150, and 200 μM). In contrast, we found that silencing of Neo1 upregulated the GC cell sensitivity to cisplatin (P < 0.05 for 100, 150 and 200 μM). These results indicated that high expression of Neo1 reduced the GC cell sensitivity to cisplatin.
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Effects of Neo1 overexpression on GC cell viability, cell motility and adhesion ability
Subsequently, we explored the effects of Neo1 overexpression on GC cell viability, cell motility and adhesion ability, together with underlying mechanisms. As demonstrated in Fig. 3A-3C , overexpression of Neo1 significantly promoted cell viability, cell motility and adhesion ability in GC cells (all P < 0.05). The potential underlying mechanism was further investigated. It has been well demonstrated that EMT is involved in cancer progression, particularly in metastasis. In combination of the results from Fig. 1 and Fig. 2 , we assumed that there might be a potential relationship between Neo1 and EMT process. Therefore, both the mRNA and protein levels of EMT related factors (E-Cadherin, N-Cadherin, and Vimentin) were measured under the condition of Neo1 abnormal expression. The EMT process of GC cells was induced by administration of TGF-β1. The results showed that TGF-β1 statistically decreased expression of E-Cadherin (P < 0.01 for both mRNA and protein), and while markedly increased expression of N-Cadherin (both mRNA and protein) and Vimentin (P < 0.01 for mRNA and P < 0.05 for protein), indicating the EMT was successfully induced. Interestingly, we found that overexpression of Neo1 could significantly decrease the expression of E-Cadherin (P < 0.05 for mRNA and P < 0.01 for protein), and while statistically increased the expression of N-Cadherin and Vimentin (P < 0.05 for both mRNA and protein), as compared to the pcDNA3.1 group. Similarly, the effects of Neo1 overexpression on EMT in cells treated with TGF-β1 were identical to that described above (P < 0.05 or P < 0.01) ( Fig. 3D and 3F) . The results implied that the increasing of cell motility and adhesion ability induced by overexpression of Neo1 was possibly associated with the enhanced EMT. 
Effects of Neo1 silence on GC cell viability, cell motility and adhesion ability
Next, the effects of Neo1 silence on the GC cell viability, cell motility and adhesion ability were investigated. As expected, we found that silencing of Neo1 significantly inhibited the cell viability, cell motility and adhesion ability in GC cells (all P < 0.05) (Fig. 4A-4C ). In addition, the results showed that suppression of Neo1 significantly upregulated expression Fig. 3 . Effects of Neo1 overexpression on GC cell viability, cell motility and adhesion ability. Neo1 was overexpressed by transfection with pc-Neo1 in SGC-7901 cells, and then the effects of Neo1 overexpression on the cell viability, cell motility and adhesion ability were determined by CCK-8 assay, wound healing assay, and adhesion assay, respectively. The results showed that overexpression of Neo1 significantly increased the cell viability (A), cell motility (B), and adhesion ability (C). The potential underlying mechanisms of cell motility and adhesion ability were further explored by analyzing the EMT process. EMT was constructed by addition of TGF-β1 to the cells. Both the mRNA and proteins levels of the key proteins in the EMT process (E-Cadherin, N-Cadherin, and Vimentin) were measured by qRT-PCR and Western blot, respectively. The results indicated that overexpression of Neo1 promoted and EMT process (D-F) in GC cells. The experiments were repeated at least three times. Data are presented as the mean ± standard deviation (SD). Neo1, neogenin-1; GC, gastric cancer; TGF, transforming growth factor; EMT, epithelial mesenchymal transition; qRT-PCR, quantitative real-time reverse transcriptase polymerase chain reaction; pc-Neo1, Neo1 expression vector. Asterisk for the TGF-β1 group indicated significance compared with control; Asterisk for the TGF-β1 + pcDNA3.1 and the pc-Neo1 groups indicated significance compared with the pcDNA3.1 group. * P<0.05, or ** P<0.01. . Effects of Neo1 silence on the GC cell viability, cell motility and adhesion ability. Neo1 was suppressed by transfection with si-Neo1 in SGC-7901 cells, and then the effects of Neo1 silence on the cell viability, cell motility and adhesion ability were determined by CCK-8 assay, wound healing assay, and adhesion assay, respectively. The results showed that silence of Neo1 significantly inhibited the cell viability (A), cell motility (B) and adhesion ability (C). The potential underlying mechanism of cell motility and adhesion ability were further explored by analyzing the EMT process. EMT was induced by addition of TGF-β1 to the cells. Both the mRNA and protein levels of the key proteins in the EMT process (E-Cadherin, N-Cadherin, and Vimentin) were measured by qRT-PCR and Western blot, respectively. The results indicated that silence of Neo1 inhibited EMT process (D-F) in GC cells. The experiments were repeated at least three times. Data are presented as the mean ± standard deviation (SD). Neo1, neogenin-1; GC, gastric cancer; si, small interfering; NC, negative control; TGF, transforming growth factor; EMT, epithelial mesenchymal transition; qRT-PCR, quantitative real-time reverse transcriptase polymerase chain reaction. Asterisk for the TGF-β1 group indicated significance compared with control; Asterisk for the TGF-β1 + siNC and the si-Neo1 groups indicated significance compared with the siNC group. * P<0.05 or ** P<0.01. of E-Cadherin (P < 0.05 for both mRNA and protein), and while statistically downregulated the expression of N-Cadherin and Vimentin (all P < 0.05). Similarly, the effects of Neo1 silencing on EMT in cells treated with TGF-β1 were identical to that described above (all P < 0.05) (Fig. 4D-4F ). In combination with the results from Fig. 3 , our data implied that Neol may act as an oncogene by promoting the cancer cell proliferation and metastasis.
Effects of Neo1 abnormal expression on ZEB1 level ZEB1 has been identified as an important inducer of EMT process, which is responsible for the increased aggressiveness and metastasis in a variety of human carcinomas [18] . Therefore, we analyzed the potential relationship between Neo1 and ZEB1. Both the mRNA and protein levels of ZEB1 were measured in cells abnormally expressing Neo1. Interestingly, the data revealed that both the mRNA and protein levels of ZEB1 were markedly upregulated by overexpression of Neo1 but down-regulated by silencing of Neo1 compared to their corresponding controls (P < 0.05) (Fig. 5 A-5C ). The results suggested that Neo1 positively regulated the level of ZEB1.
Effects of Neo1 abnormal expression on the Rac1/PI3K/AKT pathway
We further explored the underlying pathway concerning the effects of Neo1 abnormal expression on EMT process in GC cells. The PI3K/AKT pathway has been reported to be 
involved in the pathogenesis of many cancers, including GC [19] . The PI3K/AKT cascade is responsible for the GC cell apoptosis [20] , proliferation [21] , and metastasis [22] . Rac1 is a member of the Rho family of small GTPases, and PI3K has been considered as a downstream effector of Rac1 [23] . Hence, we analyzed the expression of the Rac1/PI3K/AKT pathwayrelated factors after changing the expression of Neo1. As revealed in Fig. 6A , the results showed that although the expression of Rac-1, PI3K, and AKT was not significantly changed by abnormal expression of Neo1, expression of their activated patterns including GTP-Rac1, p-PI3K, and p-AKT were significantly increased by overexpression of Neo1 but decreased by silencing of Neo1 compared to their corresponding controls (P < 0.05 or P < 0.01). The results indicated that Neo1 activated the Rac1/PI3K/AKT pathway. To further confirm that Neo1 regulated the expression of ZEB1 by activation of the Rac1/PI3K/AKT pathway, we administered the inhibitor of Rac1 (EHT1864) and inhibitor of PI3K (LY294002), respectively. Our data showed that the inhibitor of Rac1, EHT1864, decreased the expression of p-PI3K and p-AKT compared to the pc-Neo1 group (P < 0.05), suggesting that the inhibitor of Rac1 partly inactivated the PI3K/AKT pathway. However, the inhibitor of PI3K, LY294002, had no significant effect on the expression of GTP-Rac1. It is noteworthy that both the inhibitors of Rac1 and PI3K significantly inhibited the expression of ZEB1 compared to the pc-Neo1 group (P < 0.01 for EHT1864 or P < 0.001 for LY294002) ( Fig. 6 B and C) . Taken together, our results implied that Neo1 positively regulated the expression of ZEB1 by activating the Rac1/PI3K/AKT pathway, leading to the promotion of EMT process in GC cells.
Discussion
In the present study, we found that Neo1 acted as an oncogene in GC. Overexpression of Neo1 reduced the GC cell sensitivity to cisplatin and increased the cell viability, motility and adhesion ability, and the silencing of Neo1 reversed the above results. Moreover, we observed that overexpression of Neo1 promoted EMT process by positively regulating the expression of ZEB1. Furthermore, we found that Neo1 regulated the expression of ZEB1 by activating the Rac1/PI3K/AKT pathway.
An increasing number of studies have demonstrated the critical roles of Neo1 in human diseases. Neo1 has been reported to be expressed in many tissues that shows active growth [14] . However, the functional role of Neo1 is complicated. The expression levels of Neo1 vary significantly among different cancers. For example, high expression of Neo1 was found in ESCC [13] , moderate expression was displayed in pancreatic cancer [11] , and low expression was revealed in breast cancer, colon cancer and glioma [7, 10, 12] . Our study focused on the expression of Neo1 in GC. The data in our study were in line with a previous study showing high expression of Neo1 in different GC cell lines [14] . Nevertheless, the exact regulatory mechanism of Neo1 in GC is still not well understood. In order to address the problem, we altered the expression of Neo1 in GC cells by transfection with pc-Neo1 or si-Neo1, and then we analyzed the effects of aberrant expression of Neo1 on sensitivity to cisplatin, cell proliferation, and cell metastasis.
Resistance to chemotherapy has been a main obstacle for effective management of cancers [24] . However, the exact mechanism of chemo-resistance is still indistinct. Thus, understanding the mechanisms of resistance and strategies for overcoming resistance to chemotherapy is crucial for effective treatment of cancers. Cisplatin, in combination with other chemotherapeutic agents or on its own, is considered as an effective drug for treatment of various malignant tumors including GC [25, 26] . In our study, we found that overexpression of Neo1 reduced GC cell sensitivity to cisplatin, and silencing of Neo1 elevated the sensitivity, indicating that the upregulated Neo1 may contribute to the sensitivity of cisplatin-resistant in GC cells. In addition, the results demonstrated that overexpression of Neo1 increased cell viability, motility and adhesion ability in SGC-7901 cells. It has been well established that EMT is involved in the early steps of metastasis and plays significant roles in cancer progression [27] [28] [29] . Therefore, we hypothesized that the functions of Neo1 on GC [30] [31] [32] . The hallmarks of EMT are the functional loss of adherens junction protein (E-Cadherin) and gain of mesenchymal markers (N-Cadherin and Vimentin) [33] . To confirm the hypothesis, we first induced EMT by administration of TGF-β1. The low expression of E-Cadherin and high expressions of N-Cadherin and Vimentin suggested that EMT was successfully induced. In the present study, overexpression of Neo1 significantly decreased the levels of E-Cadherin and elevated the levels of N-Cadherin and Vimentin. Silencing of Neo1 reversed the results. This data implied that Neo1 aggravated the EMT process, leading to migration and invasion of GC cells. The EMT process is regulated by several factors, such as EMT-transcription factors (EMT-TFs) zinc finger/homeodomain proteins ZEB1 and ZEB2 [34] . It has been suggested that ZEB proteins are highly expressed in many cancer cells including GC cells [35] [36] [37] [38] [39] . In addition, ZEB1 was identified as an independent prognostic factor of GC, and there is a significant correlation between ZEB1 expression and diffuse phenotype in GC [38] . Previous studies suggested that a variety of factors such as microRNAs (miRNAs) and ubiquitin ligase CUL4A can regulate the EMT process by modulating ZEB1 expression [40] [41] [42] [43] [44] . Our study provided new evidence that Neo1 promoted the EMT process in GC by regulating the expression of ZEB1. We further explored the possible signaling pathway with respect to the observed results. Activation of PI3K regulates cell growth, transformation, migration, and invasion [45, 46] . The activity of PI3K is induced by the specific interaction of active Rac1 [47] . Moreover, Rac1 has been reported to activate AKT in a manner [48] . Additionally, EMTmediated motility and invasion have been revealed to activate the PI3K/AKT pathway in cancer cells [15, 49] . In the present study, the results suggested that Neo1 could elevate the levels of GTP-Rac1, p-PI3K, and p-AKT, indicating that Neo1 activated the Rac1/PI3K/AKT pathway. Furthermore, administration of the inhibitor of Rac1 (EHT1864) decreased the expression of p-PI3K and p-AKT, while administration of the inhibitor of PI3K (LY294002) had no effects on the expression of Rac1. Our results were in line with previous studies showing PI3K was a downstream effector of Rac1 [45, 46, 50] . Interestingly, the expression of ZEB1 was significantly inhibited by both of these inhibitors, implying that Neo1 positively upregulated the expression of ZEB1 by activating the Rac1/PI3K/AKT pathway.
In conclusion, our data suggest that Neo1 functions as an oncogene in GC. Neo1 promotes cell proliferation, motility, and adhesion by up-regulation of ZEB1 via activation of the Rac1/ PI3K/AKT pathway in GC cells.
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